In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.
暂无分享,去创建一个
Marc K Hellerstein | N. Chiorazzi | S. Zupo | K. Rai | M. Ferrarini | P. Koduru | J. Kolitz | G. Cutrona | M. Hellerstein | D. Cesar | Nicholas Chiorazzi | B. Messmer | D. Messmer | S. Allen | Prasad Kudalkar | E. Murphy | R. Damle | T. Wasil | Kanti R Rai | Jonathan E Kolitz | Prasad Koduru | Denise Cesar | Simona Zupo | Giovanna Cutrona | Manlio Ferrarini | Elizabeth J Murphy | Davorka Messmer | Tarun Wasil | Bradley T Messmer | Steven L Allen | Prasad Kudalkar | Rajendra N Damle
[1] Adrian Wiestner,et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.
[2] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[3] G. Guida,et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. , 2003, Blood.
[4] Arthur Weiss,et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.
[5] J. McCune,et al. Measurement in vivo of proliferation rates of slow turnover cells by 2H2O labeling of the deoxyribose moiety of DNA , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] Axel Benner,et al. Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. , 2002, Blood.
[7] T. Kipps,et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Oscier,et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.
[9] A. Tefferi,et al. Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia , 2001, British journal of haematology.
[10] M Chilosi,et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[11] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[12] P. Ghia,et al. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. , 2000, Advances in cancer research.
[13] S. Pileri,et al. The pathologist's view point. Part I--indolent lymphomas. , 2000, Haematologica.
[14] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[15] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[16] T J Hamblin,et al. B-cell chronic lymphocytic leukemia: a bird of a different feather. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[18] M. Hellerstein,et al. Measurement of cell proliferation by labeling of DNA with stable isotope-labeled glucose: studies in vitro, in animals, and in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[20] S. E. Brodie. New York, New York, USA , 1996 .
[21] R. Hoffman,et al. Hematology: Basic Principles and Practice , 1995 .
[22] P. Isaacson,et al. Proliferation centres in B‐cell malignant lymphoma, lymphocytic (B‐CLL): an immunophenotypic study , 1994, Histopathology.
[23] G. Marti,et al. Evolution of leukemic heterogeneity of human B-CLL lymphocytes between and within patients. , 1992, Current topics in microbiology and immunology.
[24] S. Chevret,et al. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. , 1991, Blood.
[25] W. Plunkett,et al. Metabolism and action of purine nucleoside analogs. , 1991, Pharmacology & therapeutics.
[26] S. Molica,et al. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia , 1987, Cancer.
[27] Ciril Rozman,et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.
[28] P. Dörmer,et al. Chronic lymphocytic leukemia: a proliferative or accumulative disorder? , 1983, Leukemia research.
[29] K. Nilsson,et al. 3H-thymidine uptake in chronic lymphocytic leukaemia cells. , 2009, Scandinavian journal of haematology.
[30] E. Cronkite,et al. Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia. , 1979, Blood.
[31] I. Chanarin,et al. Studies in chronic lymphocytic leukaemia. The kinetics of 51Cr-labelled lymphocytes. , 2009, Scandinavian journal of haematology.
[32] L. Terenius,et al. Biochemical characteristics of chronic lymphocytic leukaemia. Glucocorticoid receptors, B and T lymphocyte surface markers, concanavalin A-induced agglutination and thymidine incorporation. , 2009, Scandinavian journal of haematology.
[33] L. Debusscher,et al. Cell kinetics in chronic lymphocytic leukaemia (CLL). , 1977, Clinics in haematology.
[34] P. Schick,et al. Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients. , 1973, Blood.
[35] J. Frühling,et al. Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool". , 1973, Blood.
[36] E. Cronkite,et al. Lymphocyte kinetics in chronic lymphocytic leukaemia (CLL) studied by ECIB. , 1969, British journal of haematology.
[37] S. Perry,et al. Studies of leukocyte kinetics in chronic lymphocytic leukemia. , 1968, Blood.
[38] W. Dameshek. Special Article: Chronic Lymphocytic Leukemia—an Accumulative Disease of Immunologically Incompetent Lymphocytes , 1967 .
[39] W. Dameshek. Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes. , 1967, Blood.